Avadel Pharmaceuticals PLC AVDL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVDL is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $18.31
- Day Range
- $17.73–18.66
- 52-Week Range
- $9.50–19.04
- Bid/Ask
- $17.95 / $18.60
- Market Cap
- $1.76 Bil
- Volume/Avg
- 849,156 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 52.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 154
- Website
- https://www.avadel.com
Valuation
|
Metric
|
AVDL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 18.76 |
Price/Sales | 52.50 |
Price/Cash Flow | — |
Price/Earnings
AVDL
Financial Strength
|
Metric
|
AVDL
|
|---|---|
Quick Ratio | 3.22 |
Current Ratio | 3.64 |
Interest Coverage | −15.26 |
Quick Ratio
AVDL
Profitability
|
Metric
|
AVDL
|
|---|---|
Return on Assets (Normalized) | −78.01% |
Return on Equity (Normalized) | −233.35% |
Return on Invested Capital (Normalized) | −105.39% |
Return on Assets
AVDL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Pcmmxfwt | Qnjzb | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Nlxqrwsyn | Dwtxbg | $69.1 Bil | |
HLN
| Haleon PLC ADR | Qyfkpdpp | Djg | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Qdlnfdmp | Qdywm | $15.7 Bil | |
VTRS
| Viatris Inc | Vrwxkcql | Cjzwd | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mkzlrsmt | Cqnr | $12.4 Bil | |
CTLT
| Catalent Inc | Cbgddlxf | Wjbywxl | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Dcybpmyc | Ssphy | $4.5 Bil | |
CURLF
| Curaleaf Holdings Inc | Pgjccwhwb | Rhsl | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Qwvjcjxv | Fxyghhy | $3.5 Bil |